成人亚洲性情网站w_男女激烈床震gif动态图免费_AA网站在线观看_有码的中文av无码的中文av_eeyyss日韩电影无码_亚洲伦另类中文字幕_日韩伦理在线播放成人免费_欧美日韩国产亚洲一区二区三区_局长含着我的奶边摸边做视频_了解最新国产黑丝精品

SignalChem

SignalChem優(yōu)勢(shì)提供人類重組蛋白，用于研究細(xì)胞信號(hào)傳導(dǎo)的生物技術(shù)領(lǐng)域。生產(chǎn)供應(yīng)高活性激酶、磷酸酶、磷酸二酯酶、組蛋白脫乙酰酶、沉默信息素和參與信號(hào)轉(zhuǎn)導(dǎo)的其他細(xì)胞蛋白、抗體、肽底物等。包括定制蛋白質(zhì)開發(fā)和化合物分析。

SignalChem Lifesciences Corporation (SLC) is a biotechnology company registered in British Columbia, Canada. It has two arms of business: the bioreagent and service business and the drug discovery and development business. The bioreagent and service business was started as SignalChem Pharmaceuticals Inc (SCP) at its inception in 2004. SCP initially focused on producing kinase-related products to facilitate biomedical research and drug discovery efforts. The company’s current product line is more than 2000 which covers almost all the kinase targets of the entire kinome and the assays, epigenetic enzymes and assays, other signalling proteins and tools and services etc. The products created by the bioreagent business have given a significant advantage to SLC in its quest to generate novel drug candidates quickly and cost-effectively and this revenue generating business has been the foundation of the company’s drug discovery platform.

SLC’s drug discovery and development arm of business focuses on finding novel small molecule kinase inhibitors for the treatment of human diseases with unmet medical needs. Coupling with our library of unique kinase-specific small molecule compounds, our experiences and expertise in the kinase allow us to deliver novel therapies against new and difficult-to-drug targets with a greater likelihood of success and better outcomes for patients. This powerful target discovery engine has generated a robust drug candidate pipeline of novel kinase inhibitors for the treatment different type of cancers.In addition, the bioreagent products can also be used to develop diagnostic kits (Biomarkers) to support discovery and development of drug candidates using a personalized medicine approach. This entails identifying those patients with the related kinase defect and applying a specific targeted therapy against the defective kinase which will improve SLC’s prospects of successful clinical development and improved patient outcome.

產(chǎn)品列表：